Sign In

Henry Levy

President, Life Sciences and Healthcare at Clarivate

Henry Levy is the President of Life Sciences & Healthcare at Clarivate, a global leader in providing trusted intelligence and analytics to accelerate innovation. He assumed this role on May 1, 2023.12

Professional Background

Henry Levy brings over 25 years of experience in the life sciences industry to his position at Clarivate.1 Prior to joining Clarivate, he held several key roles at Veeva Systems, a cloud software company for the life sciences industry, including:

  • President of Global R&D and Quality
  • Chief Strategy Officer
  • General Manager for the Clinical Data Management product suite12

Before his tenure at Veeva Systems, Levy served as:

  • Chief Commercial Officer at PPD, where he developed new partnership models between biopharmaceutical companies and contract research organizations
  • Leader of Accenture's global life sciences R&D practice, where he worked with 90% of the top 20 biopharmaceutical companies12

Responsibilities at Clarivate

As President of Life Sciences & Healthcare, Henry Levy is responsible for:

  • Accelerating growth in the Life Sciences & Healthcare segment
  • Supporting companies from early-stage drug discovery to commercialization
  • Leading teams focused on developing solutions that enable life sciences and healthcare companies to improve patient lives through transformative intelligence and data technology24

Expertise and Contributions

Henry Levy is recognized as a life sciences expert who has:

  • Published multiple articles on drug development and technology trends
  • Frequently speaks at industry forums12

Education

He holds a bachelor's degree in bioengineering from the University of Pennsylvania.34

Henry Levy's appointment at Clarivate is part of the company's strategy to strengthen its executive leadership team and drive growth in key market segments.12

Highlights

Jul 29 · linkedin

The integration of machine learning (ML) and real-world data (RWD) is gaining momentum, particularly in the field of rare diseases and specialized medicine, offering a powerful tool for the pharmaceutical industry to deliver targeted treatments to patients in need. Recent data from the National Organization for Rare Disorders (NORD), as highlighted in a Clarivate report, reveals a critical reality: over 90% of rare diseases lack an FDA-approved treatment. With an estimated 350 million people worldwide affected by some form of rare disease, including 25-30 million Americans, the urgency to find solutions is clear. Today, RWD represents a crucial asset in providing a comprehensive picture of rare diseases. It allows life science companies to explore epidemiological aspects, drawing data from diverse sources such as electronic health records (EHR) and scientific literature. Simultaneously, applying ML to RWD opens doors to uncovering hidden patterns and associations, generating actionable insights that can accelerate advancements in drug development and commercialization. However, to ensure the success of this approach, it’s fundamental to establish rigorous data management practices, privacy protocols, and ethical standards. These measures are imperative to protect patient confidentiality, uphold data quality and integrity, and mitigate regulatory risks associated with the use of RWD and ML. #Clarivate #Pharma #Healthcare #Innovation #RWD #ML #RareDiseases

Jul 8 · linkedin

AI-enabled precision medicine is transforming healthcare by offering precise, personalized treatments. By analyzing vast healthcare data in real-time, AI can create therapies that reduce disease prevalence, improve outcomes, and lower costs, making healthcare more effective and accessible.   Integrating AI into healthcare operations is a game-changer. It enhances diagnostic and treatment precision, meeting the demand for personalized care while keeping pace with advancements. AI adoption boosts treatment accuracy, patient outcomes, and operational efficiency.   In the biopharmaceutical space, AI and machine learning revolutionize drug discovery, development, and delivery. They identify promising drug candidates, offer disease insights and manage extensive data. The challenge is leveraging these benefits and overcoming the learning curve by targeting the right molecules and patients.   Companies like Exscientia, with AI-designed drugs in trials, and innovations like Google DeepMind's AlphaFold 3, predicting protein interactions, show how AI can accelerate research and discovery. But a key question remains: Are regulators ready for these rapid advancements? Fully integrating AI into healthcare promises significant strides toward a healthier future for all.   #AI #PrecisionMedicine #Pharma #Innovation #Biotech #DrugDiscovery #MachineLearning #FutureOfMedicine

Related Questions

What are Henry Levy's main responsibilities at Clarivate?
How did Henry Levy's role at Veeva Systems prepare him for his position at Clarivate?
What are some of Henry Levy's notable achievements in the life sciences industry?
How does Clarivate plan to benefit from Henry Levy's expertise?
What are the future goals for Henry Levy at Clarivate?
Henry Levy
Henry Levy, photo 1
Henry Levy, photo 2
Add to my network

Location

Wynnewood, Pennsylvania, United States